Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -1.02

Oncopeptides AB (publ) Price to Earnings Ratio (P/E) is -1.02 on January 14, 2025, a 41.79% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Oncopeptides AB (publ) 52-week high Price to Earnings Ratio (P/E) is -0.90 on November 11, 2024, which is 11.96% above the current Price to Earnings Ratio (P/E).
Oncopeptides AB (publ) 52-week low Price to Earnings Ratio (P/E) is -1.98 on August 13, 2024, which is -93.29% below the current Price to Earnings Ratio (P/E).
Oncopeptides AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.46.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years